Statin use and hospitalization for sepsis in patients with chronic kidney disease

被引:91
作者
Gupta, Rajesh
Plantinga, Laura C.
Fink, Nancy E.
Melamed, Michal L.
Coresh, Josef
Fox, Caroline S.
Levin, Nathan W.
Powe, Neil R.
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
[5] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA
[6] Albert Einstein Coll Med, Dept Epidemiol, Bronx, NY 10467 USA
[7] Albert Einstein Coll Med, Dept Populat Hlth, Bronx, NY 10467 USA
[8] Blood Inst Framingham Heart Study, Framingham, MA USA
[9] Renal Res Inst, New York, NY USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2007年 / 297卷 / 13期
关键词
CHRONIC-HEMODIALYSIS PATIENTS; PLACEBO-CONTROLLED TRIAL; COA REDUCTASE INHIBITOR; REACTIVE PROTEIN-LEVELS; DIALYSIS PATIENTS; RISK-FACTORS; IMPROVES SURVIVAL; UNITED-STATES; IN-VIVO; MORTALITY;
D O I
10.1001/jama.297.13.1455
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Patients with chronic kidney disease are at high risk for sepsis and sepsis-related mortality. Objective To assess whether statin use is associated with a reduction in hospitalizations for sepsis in dialysis patients. Design, Setting, and Patients National prospective cohort study that enrolled 1041 incident dialysis patients at 81 US not-for-profit outpatient dialysis clinics from October 1995 to June 1998, with follow-up to January 2005. Statin use was determined by medical record review. Rates of hospitalization for sepsis between statin users and control patients were compared using multivariate regression models, with adjustment for potential confounders in the overall cohort and in a subcohort in which control patients were matched to statin users according to their likelihood ( propensity) to have been prescribed a statin. Main Outcome Measure Hospitalizations for sepsis were determined through hospital records from the United States Renal Data System ( mean follow-up, 3.4 years). Results There were 303 hospitalizations for sepsis. Rates of sepsis-related hospitalizations were significantly lower in patients receiving statins ( crude incidence rate, 41/ 1000 patient-years) than in those not receiving statins ( crude incidence rate, 110/ 1000 patient-years) ( P <. 001). With adjustment for demographics and dialysis modality, statin users were substantially less likely to be subsequently hospitalized for sepsis ( incidence rate ratio, 0.41; 95% confidence interval [CI], 0.25-0.68). Further adjustment for comorbidities and laboratory values continued to show this protective association ( incidence rate ratio, 0.38; 95% CI, 0.21-0.67). In the propensity-matched subcohort, statin use was even more protective ( incidence rate ratio, 0.24; 95% CI, 0.11-0.49). Conclusions Use of statins was strongly and independently associated with a reduction in the risk of hospitalization for sepsis in patients who had chronic kidney disease and were receiving dialysis. Randomized trials of statins in patients with chronic kidney disease should examine the prevention of sepsis as a potentially important benefit.
引用
收藏
页码:1455 / 1464
页数:10
相关论文
共 45 条
[1]  
Aikawa M, 2001, CIRCULATION, V103, P276
[2]   Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].
Albert, MA ;
Danielson, E ;
Rifai, N ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70
[3]   Prior statin therapy is associated with a decreased rate of severe sepsis [J].
Almog, Y ;
Shefer, A ;
Novack, V ;
Maimon, N ;
Barski, L ;
Eizinger, M ;
Friger, M ;
Zeller, L ;
Danon, A .
CIRCULATION, 2004, 110 (07) :880-885
[4]  
Ando H, 2000, J PHARMACOL EXP THER, V294, P1043
[5]   Type of vascular access and survival among incident hemodialysis patients: The choices for healthy outcomes in caring for ESRD (CHOICE) study [J].
Astor, BC ;
Eustace, JA ;
Powe, NR ;
Klag, MJ ;
Fink, NE ;
Coresh, J .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (05) :1449-1455
[6]   Comorbidity assessment in hemodialysis and peritoneal dialysis using the index of coexistent disease [J].
Athienites, NV ;
Miskulin, DC ;
Fernandez, G ;
Bunnapradist, S ;
Simon, G ;
Landa, M ;
Schmid, CH ;
Greenfield, S ;
Levey, AS ;
Meyer, KB .
SEMINARS IN DIALYSIS, 2000, 13 (05) :320-326
[7]   Study of Heart and Renal Protection (SHARP) [J].
Baigent, C ;
Landry, M .
KIDNEY INTERNATIONAL, 2003, 63 :S207-S210
[8]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[9]   INCIDENCE, RISK-FACTORS, AND OUTCOME OF SEVERE SEPSIS AND SEPTIC SHOCK IN ADULTS - A MULTICENTER PROSPECTIVE-STUDY IN INTENSIVE-CARE UNITS [J].
BRUNBUISSON, C ;
DOYON, F ;
CARLET, J ;
DELLAMONICA, P ;
GOUIN, F ;
LEPOUTRE, A ;
MERCIER, JC ;
OFFENSTADT, G ;
REGNIER, B .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (12) :968-974
[10]   Salmonella enterica serovar typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation [J].
Catron, DM ;
Lange, Y ;
Borensztajn, J ;
Sylvester, MD ;
Jones, BD ;
Haldar, K .
INFECTION AND IMMUNITY, 2004, 72 (02) :1036-1042